PLK1 and cancer: Of these, a number of polo-like kinase (PLK) inhibitors, that either target the ATP-binding site [30–34] or the unique Polo-box domain [35, 36], have attracted our interest (see below) as a number of these are progressing pre-clinically or clinically as anti-cancer agents (S1 Table).